Jung E. Choi

Ms. Choi joined GBT in April 2015 as chief business and strategy officer. She is responsible for spearheading the company’s business development activities and corporate strategy, including identifying and executing strategic transactions to drive corporate value. She also oversees patient advocacy, government affairs and policy, and program team leadership for a clinical program. During her career, Ms. Choi has led or managed over 50 transactions exceeding $13 billion in value. Prior to GBT, she served as senior vice president, corporate development, for InterMune, Inc. (acquired by Roche Holding AG). Before that, Ms. Choi served as senior vice president, corporate development, and consultant for Chimerix, Inc. Prior to that, she held various management positions at Gilead Sciences, Inc., including leadership of business development, licensing and mergers and acquisition activities. During her tenure at Gilead, she built and oversaw the corporate development group and led the U.S. commercial launch of Hepsera® for the treatment of chronic hepatitis B. She also has venture capital and strategy experience, having served as a vice president at Bay City Capital and an engagement manager at McKinsey & Company. Ms. Choi currently serves on the board of directors of Annexon Biosciences. She is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Ms. Choi received a B.A. in human biology and an M.B.A. from Stanford University.